CoChat

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

Open access
Zhang, Liwen, McCabe, Timothy, Condra, Jon H., Ni, Yan G., Peterson, Laurence B., Wang, Weirong, Strack, Alison M., Wang, Fubao, Pandit, Shilpa, Hammond, Holly, Wood, Dana, Lewis, Dale, Rosa, Ray, Mendoza, Vivienne, Cumiskey, Anne Marie, Johns, Douglas G., Hansen, Barbara C., Shen, Xun, Geoghagen, Neil, Jensen, Kristian, Zhu, Lei, Wietecha, Karol, Wisniewski, Douglas, Huang, Lingyi, Zhao, Jing Zhang, Ernst, Robin, Hampton, Richard, Haytko, Peter, Ansbro, Frances, Chilewski, Shannon, Chin, Jayne, Mitnaul, Lyndon J., Pellacani, Andrea, Sparrow, Carl P., An, Zhiqiang, Strohl, William, Hubbard, Brian, Plump, Andrew S., Blom, Daniel, Sitlani, Ayesha · 2012 · International Journal of Biological Sciences
Cited by 101

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and antagonizes PCSK9 function in-vitro. In CETP/LDLR-hemi mice two successive doses of 1B20, administered 14 days apart at 3 or 10 mpk, induced dose dependent reductions in LDL-cholesterol (≥ 25% for 7-14 days) that correlated well with the extent of PCSK9 occupancy by the antibody. In addition, 1B20 induces increases in total plasma antibody-bound PCSK9 levels and decreases in liver mRNA levels of SREBP-regulated genes PCSK9 and LDLR, with a time course that parallels decreases in plasma LDL-cholesterol (LDL-C). Consistent with this observation in mice, in statin-responsive human primary hepatocytes, 1B20 lowers PCSK9 and LDLR mRNA levels and raises serum steady-state levels of antibody-bound PCSK9. In addition, mRNA levels of several SREBP regulated genes involved in cholesterol and fatty-acid synthesis including ACSS2, FDPS, IDI1, MVD, HMGCR, and CYP51A1 were decreased significantly with antibody treatment of primary human hepatocytes. In rhesus monkeys, subcutaneous (SC) dosing of 1B20 dose-dependently induces robust LDL-C lowering (maximal ~70%), which is correlated with increases in target engagement and total antibody-bound PCSK9 levels. Importantly, a combination of 1B20 and Simvastatin in dyslipidemic rhesus monkeys reduced LDL-C more than either agent alone, consistent with a mechanism of action that predicts additive effects of anti-PCSK9 agents with statins. Our results suggest that antibodies targeting PCSK9 could provide patients powerful LDL lowering efficacy on top of statins, and lower cardiovascular risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/ijbs.3524

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Zhang, L., McCabe, T., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H., Wood, D., Lewis, D., Rosa, R., Mendoza, V., Cumiskey, A. M., Johns, D. G., Hansen, B. C., Shen, X., Geoghagen, N., Jensen, K., Zhu, L., Wietecha, K., Wisniewski, D., Huang, L., Zhao, J. Z., Ernst, R., Hampton, R., Haytko, P., Ansbro, F., Chilewski, S., Chin, J., Mitnaul, L. J., Pellacani, A., Sparrow, C. P., An, Z., Strohl, W., Hubbard, B., Plump, A. S., Blom, D., & Sitlani, A.
Venue
International Journal of Biological Sciences
Published
2012
Volume
8
Issue
3
Pages
310-327
ISSN
1449-2288 (ISSN-L)
OpenAlex
W2131607570
Cited by
101
References
12
FWCI
10.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.